Home » Topics » Regulatory » EMA

EMA
RSS

Cladribine tablet MAA accepted for review by EMA

July 18, 2016

EMA accepts for review MAA for adalimumab biosimilar SB-5

July 18, 2016

EMA committee recommends orphan drug designation for Akari's Coversin

July 13, 2016

EMA's review of conditional MAA for masitinib to follow standard timeline

July 5, 2016

EMA grants an expansion to orphan drug designation for ATIR-101

July 5, 2016

EMA committee recommends granting orphan drug designation to Vicore's C-21 in IPF

June 29, 2016

EMA recommends approval of Keytruda for advanced NSCLC

June 28, 2016

Puma submits MAA to the EMA for neratinib

June 28, 2016

EMA's CHMP grants positive opinion to Teva's reslizumab

June 27, 2016

EMA validates Santhera's MAA for Raxone in Duchenne muscular dystrophy

June 22, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...